NurExone Biologic Inc.
NRX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 4.70% | -26.59% | 4.78% | 20.64% | -10.01% |
| Total Depreciation and Amortization | 5.36% | 5.66% | 12.77% | 11.90% | -2.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.57% | 22.44% | 9.73% | 5.11% | 0.00% |
| Change in Net Operating Assets | 418.75% | 116.58% | 1.03% | -145.99% | 26.19% |
| Cash from Operations | 22.65% | -5.28% | 8.57% | -20.34% | -8.22% |
| Capital Expenditure | 200.00% | 77.78% | 25.00% | -500.00% | 93.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 200.00% | 77.78% | 25.00% | -500.00% | 93.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -12.50% | 20.00% | -25.00% | -700.00% | 66.67% |
| Issuance of Common Stock | -31.91% | -72.26% | 113.27% | -32.75% | 74.26% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -27.20% | -72.49% | 113.94% | -33.21% | 74.73% |
| Foreign Exchange rate Adjustments | 173.33% | -122.73% | 700.00% | -109.24% | 3,075.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 19.75% | -154.37% | 571.43% | -138.28% | 671.43% |